These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11798062)

  • 21. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.
    Rothwell PM
    Lancet; 2005 Jan 8-14; 365(9454):176-86. PubMed ID: 15639301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to deal with multiple treatment or dose groups in randomized clinical trials?
    Hothorn LA
    Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses.
    Contopoulos-Ioannidis DG; Seto I; Hamm MP; Thomson D; Hartling L; Ioannidis JP; Curtis S; Constantin E; Batmanabane G; Klassen T; Williams K
    Pediatrics; 2012 Jun; 129 Suppl 3():S161-84. PubMed ID: 22661763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of epidural injections for spinal stenosis published in the New England Journal of Medicine: further confusion without clarification.
    Manchikanti L; Candido KD; Kaye AD; Boswell MV; Benyamin RM; Falco FJ; Gharibo CG; Hirsch JA
    Pain Physician; 2014; 17(4):E475-88. PubMed ID: 25054398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The quality of reports of randomized trials in multiple sclerosis: a review.
    Signori A; Baccino A; Sormani MP
    Mult Scler; 2012 Jun; 18(6):776-81. PubMed ID: 22495947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the biology of sex and gender differences: using subgroup analysis and statistical design to detect sex differences in clinical trials.
    Keitt SK; Wagner CR; Tong C; Marts SA
    MedGenMed; 2003 Jun; 5(2):39. PubMed ID: 14603138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
    Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
    J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Roaming through methodology. IX. The interpretation of subgroup analyses].
    van der Windt DA; van Poppel MN
    Ned Tijdschr Geneeskd; 1998 Oct; 142(41):2245-7. PubMed ID: 9864501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How to interpret subgroup analyses in cardiovascular trials?].
    Basile C; Maggioni AP
    G Ital Cardiol (Rome); 2024 Jul; 25(7):509-517. PubMed ID: 38916466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.
    Dane A; Spencer A; Rosenkranz G; Lipkovich I; Parke T;
    Pharm Stat; 2019 Mar; 18(2):126-139. PubMed ID: 30592133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Level of evidence for promising subgroup findings: The case of trends and multiple subgroups.
    Tanniou J; Smid SC; van der Tweel I; Teerenstra S; Roes KCB
    Stat Med; 2019 Jun; 38(14):2561-2572. PubMed ID: 30868624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them?
    Tanniou J; van der Tweel I; Teerenstra S; Roes KCB
    Pharm Stat; 2017 Jul; 16(4):280-295. PubMed ID: 28503861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical Properties of the Design for Simultaneous Global Drug Development Program.
    Liu K; Yuan Z; Chen G; Huang Q; Wenrich J
    J Biopharm Stat; 2015; 25(6):1135-44. PubMed ID: 25321600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subgroup analysis in MS trials.
    Sormani MP
    Mult Scler; 2017 Jan; 23(1):34-35. PubMed ID: 26772964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Planning controlled clinical trials on the basis of descriptive data analysis.
    Abt K
    Stat Med; 1991 May; 10(5):777-95. PubMed ID: 2068431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A statistical primer on subgroup analyses.
    Milojevic M; Nikolic A; Jüni P; Head SJ
    Interact Cardiovasc Thorac Surg; 2020 Jun; 30(6):839-845. PubMed ID: 32215640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.